A randomized Phase II Study of Bevacizumab in Combination with Docetaxel or S-1 in Patients with Non-Squamous Non-Small-Cell Lung Cancer Previously Treated with Platinum based Chemotherapy
- Conditions
- on-Squamous Non-Small-Cell Lung Cancer
- Registration Number
- JPRN-UMIN000003533
- Lead Sponsor
- Hanshin Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 90
Not provided
1)interstitial pneumonia or pulmonary fibrosis detectable on CT scan 2)history of drug induced interstitial pneumonia 3)history of severe drug allergy 4)patients previously treated with S-1 and docetaxel. 5)history of active infection or other serious disease condition 6)history of poorly controlled pleural effusion,pericardial effusion and ascites 7)history of severe heart disease(uncontrollable arrythmia,uncontrollable angina pectoris,heart failure, etc.) 8)uncontrollable hypertension 9)uncontrollable diabetes mellitus 10)curative radiotherapy pretreated to the chest. 11)current history of hemosputum 12)current or previous history hemoptysis 13)current or previous (within the last 1 year) history of cerebrovascular disease 14)current or previous (within the last 1 year) history of GI perforation 15)symptomatic brain metastasis 16)traumatic fracture of unrecovery 17)the operation has been scheduled for the examination period 18)tumor invasive to the chest large blood vessel. Cavity in brain or lung tumor 19)evidence of bleeding diathesis or coagulopathy 20)thrombosis that need to treat 21)severe drug allergy for 80 polysorbate content medicine 22)patients using Flucytosine 23)patients with contraindication of medication (DTX,S-1). 24)history of active double cancer 25)history of active psychological disease 26)history of pregnancy or lactation 27)any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Response rate Overall survival Disease control rate Rate of adverse events